Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.
Conditions Studied
Interventions
- DRUG PF-08046876
Study Locations (20)
California
- City of Hope National Medical Center — Duarte
- City of Hope at Irvine Lennar — Irvine
- Ronald Reagan UCLA Medical Center — Los Angeles
- UCLA Department of Medicine-Hematology/Oncology — Los Angeles
- Santa Monica UCLA Medical Center & Orthopaedic Hospital — Santa Monica
- UCLA Hematology/Oncology - Santa Monica — Santa Monica
Texas
- The University of Texas MD Anderson Cancer Center - Conroe — Conroe
- University of Texas MD Anderson Cancer Center — Houston
- The University of Texas, MD Anderson Cancer Center - West Houston — Houston
- The University of Texas, MD Anderson Cancer Center - League City — League City
- NEXT Oncology — San Antonio
Connecticut
- Smilow Cancer Hospital - Yale New Haven Health — New Haven
- Yale - New Haven Hospital - Yale Cancer Center — New Haven
- Smilow Cancer Hospital Phase 1 Unit — New Haven
- Smilow Cancer Hospital - Trumbull — Trumbull
Massachusetts
- Brigham and Women's Hospital — Boston
- Dana-Farber Cancer Institute — Boston
- Dana-Farber Cancer Institute - Chestnut Hill — Newton
Tennessee
- Sarah Cannon Research Institute - Pharmacy — Nashville
- SCRI Oncology Partners — Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2025-08-20 |
| Est. Completion | 2029-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07090499
The ClinicalTrials.gov registry entry for NCT07090499 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention — of which PF-08046876 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07090499 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Texas, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07090499 about?
NCT07090499 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors". The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs ...
What is the current status of trial NCT07090499?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2025-08-20. Estimated completion is 2029-07-08.
What conditions does trial NCT07090499 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Bladder Cancer, Esophageal Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07090499?
The interventions under investigation include: PF-08046876 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07090499?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07090499 being conducted?
This trial has 20 study locations across California, Connecticut, Massachusetts, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.